GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laboratorio Reig Jofre SA (XMAD:RJF) » Definitions » EV-to-Revenue

Laboratorio Reig Jofre (XMAD:RJF) EV-to-Revenue : 1.58 (As of Apr. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Laboratorio Reig Jofre EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Laboratorio Reig Jofre's enterprise value is €250.4 Mil. Laboratorio Reig Jofre's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €158.9 Mil. Therefore, Laboratorio Reig Jofre's EV-to-Revenue for today is 1.58.

The historical rank and industry rank for Laboratorio Reig Jofre's EV-to-Revenue or its related term are showing as below:

XMAD:RJF' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.43   Med: 1.33   Max: 12.72
Current: 1.58

During the past 13 years, the highest EV-to-Revenue of Laboratorio Reig Jofre was 12.72. The lowest was 0.43. And the median was 1.33.

XMAD:RJF's EV-to-Revenue is ranked better than
65.82% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.295 vs XMAD:RJF: 1.58

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-29), Laboratorio Reig Jofre's stock price is €2.58. Laboratorio Reig Jofre's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €2.03. Therefore, Laboratorio Reig Jofre's PS Ratio for today is 1.27.


Laboratorio Reig Jofre EV-to-Revenue Historical Data

The historical data trend for Laboratorio Reig Jofre's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorio Reig Jofre EV-to-Revenue Chart

Laboratorio Reig Jofre Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.18 1.65 1.32 0.83 0.71

Laboratorio Reig Jofre Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.84 0.83 1.84 1.55 0.71

Competitive Comparison of Laboratorio Reig Jofre's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorio Reig Jofre's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Laboratorio Reig Jofre's EV-to-Revenue falls into.



Laboratorio Reig Jofre EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Laboratorio Reig Jofre's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=250.440/158.897
=1.58

Laboratorio Reig Jofre's current Enterprise Value is €250.4 Mil.
Laboratorio Reig Jofre's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €158.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorio Reig Jofre  (XMAD:RJF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Laboratorio Reig Jofre's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.58/2.032
=1.27

Laboratorio Reig Jofre's share price for today is €2.58.
Laboratorio Reig Jofre's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorio Reig Jofre EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Laboratorio Reig Jofre's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorio Reig Jofre (XMAD:RJF) Business Description

Traded in Other Exchanges
Address
Avenida de les Flors, Sant Joan Despi, Barcelona, ESP, 08970
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.